Skip to content
‹ Back to IndustriesSciences

The Tools Leading The Science Community to New Discoveries

Many of our technological advances are used first by the scientific community. Nuclear magnetic resonance machines to analyze molecular structures were turned in the MRI machine used in hospitals, for example. 3D printers were used by scientists before they entered industry. The internet was created for scientific usage before becoming more generally available to the…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Troy Camplin · · AiAutomationQuantum ComputingScience
Share
The Tools Leading The Science Community to New Discoveries

Key takeaways

01

Many of our technological advances are used first by the scientific community.

02

Nuclear magnetic resonance machines to analyze molecular structures were turned in the MRI machine used in hospitals, for example.

03

3D printers were used by scientists before they entered industry.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Many of our technological advances are used first by the scientific community. Nuclear magnetic resonance machines to analyze molecular structures were turned in the MRI machine used in hospitals, for example. 3D printers were used by scientists before they entered industry. The internet was created for scientific usage before becoming more generally available to the public, especially through the subsequent development of the world wide web.

So, what are scientists using these days?

Artificial Intelligence

One thing scientists are using more and more is artificial intelligence (AI). AI is being used in what is called augmented analytics to better analyze data and to find patterns that may not be as obvious to humans. Human-AI interactions are resulting in new theories and hypotheses to be tested in the lab. It will be interesting to see what happens as people in-turn put the results of those experiments back into the AI for further refinement of those theories and the development of even more testable hypotheses.

The amount of data collected for all things from science to business has entered the zettabyte era (that is sextillion bytes), meaning it is becoming increasingly impossible for humans to deal with it all. Only AI is even remotely capable of handling this amount of data—an amount which is only increasing each and every moment.

Quantum Computers

Machine learning is going to take a quantum leap the moment quantum computers become fully feasible—and that moment is rapidly approaching. Right now, it is well within the realm of scientific research, in no small part because of the problems with cooling such a system, but it is expected that quantum computing will become more widely available in the next several years.

In the meantime, the development of quantum computing itself will provide researchers with more scientific knowledge about quantum physics and how we can use that knowledge to create more powerful computers and AI. After all, we are still working out exactly how quantum computers do their calculations and knowing that will lead to the design of even better quantum computers.

Quantum computers will help scientists fully integrate complex data, better analyze complex systems and processes, and thus help make better pattern predictions for such systems. This will help not only the physical and biological sciences, but also the more complex social and psychological sciences where reductionist methods have proven less than sufficient to help us understand these processes.

Robots

Robotics is another area which will no doubt impact science. The continuing development of more refined movement will allow field scientists to use robots to reach places that might have otherwise been too dangerous for a human, and it will allow scientists in the lab to engage in more precise manipulations of living and physical objects. The development of soft robotics will further open up research possibilities in more difficult-to-reach areas.

Robotic process automation will also help scientists a great deal more. Many lab processes have been automated, but many more can be. This will free scientists up to do more research, to better keep up with the reading and to do more of the mental work of science rather than having to spend quite so much time doing simple repetitive jobs. The more such technology permeates, the more even the small labs at small colleges will be automated, and the more those scientists can contribute.

Technology is transforming science every bit as much as it does business and our personal lives. Usually, the scientists get the first shot at the most recent technological innovations, trying them out and using them to advance our knowledge. It is sometimes hard to imagine what can come out of scientific instruments—who would have expected body imaging from a chemical structure analysis tool? So long as people are free to think and innovate, we will continue to see technological advances emerging out of the lab and into our living rooms.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

TC
Troy Camplin
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

TC
Troy Camplin

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512